Audited Final Results

Summary by AI BETAClose X

Silverwood Brands plc reported audited final results for the eighteen months ended 30 June 2025, with revenue of £23,915,915 and a statutory loss before tax of £18,297,449, though management views EBITDA positively at £496,488. The company experienced a delay in publication due to complexities in translating Japanese subsidiaries' financial statements, leading to a temporary suspension of its shares. During the period, Silverwood acquired Cosme Science Corporation and its subsidiary Dr. Baeltz, enhancing its production capabilities. The group's total assets decreased to £20,702,806 from £31,716,225 in the prior period, while total liabilities increased to £19,279,128 from £16,813,520, resulting in net assets of £1,423,678 compared to £14,902,705.

Disclaimer*

Silverwood Brands PLC
20 April 2026
 

Silverwood Brands Plc

("Silverwood" or the "Company", together with its subsidiaries, the "Group")

Audited Final Results for the 18x months ended 30 June 2025

Silverwood Brands plc (AQSE: SLWD), a holding company established to invest primarily in branded consumer businesses, announces the Group's audited final results in respect of the eighteen months ended 30 June 2025.

 

Chief Executive's Statement

Delay in Publication

Before turning to the Group's performance for the period, I want to speak directly to the delay in publishing our audited results and the resulting temporary suspension of trading in the Company's shares.

The deadline for filing our annual report was not met. As we set out in our December update, completion of the audit was prolonged by the technically demanding process of translating the financial statements of our Japanese subsidiaries from Japanese Generally Accepted Accounting Principles (Japanese GAAP) to International Financial Reporting Standards (IFRS). This work proved more complex and timeintensive than anticipated.

Our structure of small brands supported by lean teams means that technical gaps can surface through the audit process. Strengthening our financial reporting capability is therefore a priority. We are investing in additional expertise and capacity to ensure that our reporting processes are robust, resilient, and able to meet the expectations of a listed company.

We recognise the seriousness of missing a regulatory deadline and the impact of the suspension on our shareholders. On behalf of the Board, I apologise for the delay in publishing these results and reaffirm our commitment to restoring confidence through improved systems, strengthened teams, and timely reporting going forward.

As a result of the delay, we are publishing this RNS alongside our unaudited interim results for the six months to 31 December 2025.

 

Introduction

Silverwood exists to build purposeful, resilient brands; businesses with a clear reason to exist and the discipline to grow through customer obsession, longterm thinking, and pride in both product and operational excellence. We began the period with four distinct beauty brands: Steamcream, Cigarro, Balmonds, and Nailberry, each with strong positioning and meaningful longterm potential.

In March 2024, we strengthened the group further through the acquisition of Cosme Science Corporation and its subsidiary Dr. Baeltz, bringing a premier Japanese research and OEM manufacturer with a 40year legacy into the Silverwood family. This acquisition enhances our production capabilities, deepens our technical expertise, and opens new avenues for innovation and growth.

Across the period, we expanded distribution, improved product quality, refreshed brand assets for international expansion, and continued to build strong teams. Customer feedback remains consistently positive, reinforcing our confidence in the brands we are developing.

As J. P. Getty famously said, "Rise early, work hard, strike oil."

We have assembled a portfolio where teams rise early and work hard-and we believe this disciplined approach will deliver longterm value. Our focus remains on growing our brands and assessing new acquisition opportunities as they arise.

 

Business Review

We operate a portfolio of highpotential brands that we aim to grow significantly over the long term. While performance for smaller, scaling brands can vary over shorter periods, we remain confident that disciplined execution, channel expansion, and continued investment in our capabilities will deliver a clear trajectory of profitable growth over time.

For the eighteenmonth period ended 30 June 2025, the Group recorded a statutory loss before tax of £18,297,449. As set out in the reconciliation below, a number of accounting adjustments required under IFRS materially distort the view of underlying trading. On a managementview basis, the business delivered a positive EBITDA of £496,488, which we believe provides a clearer reflection of operational performance.

Revenue

 

23,915,915

 

Statutory Profit/(Loss) Before Tax IFRS Basis

 

(18,297,449)

 





Reconciling Items




Post Combination Renumeration



(6,468,126)

Impairment



22,145,978

Acquisition and legal costs



124,361

Depreciation and Other Fixed Asset Costs



4,305,842

Gain on Bargain Purchase



(2,154,585)

Interest Receivable



(51,201)

Interest Payable



891,668




Management EBITDA View

 

496,488

 

 

A detailed breakdown of the reconciling items along with a brand-by-brand analysis are available in the full audited financial statements which are published on our website.

 

 

 

 

 

Consolidated Statement of Comprehensive Income


18 Months Ended 30 June 2025

 

As Restated: 12 Months Ended 31 December 2023

 




Revenue

23,915,915

 

11,094,983

Cost of Sales

(9,768,645)


(1,680,488)

Gross Profit

14,147,270

 

9,414,495





Other Operating Income

16,726


26,799

Selling and Distribution

(2,259,918)


(1,531,628)

Administrative Expenses

(15,713,432)


(9,645,972)

Exceptional Charges




Non-recurring Costs

(109,552)


-

Impairment

(22,145,978)


(219,644)

Acquisition costs, acquisition related contingent considerations and earn-outs

8,607,902


(3,842,615)

Loss from Operations

(17,456,982)

 

(5,798,565)





Finance Income

51,201


41,649

Finance Expense

(891,668)


(805,786)

Loss Before Tax

(18,297,449)

 

(6,562,702)





Tax Expense

1,539,667


471,528

Loss for the period

(16,757,782)

 

(6,091,174)





Items that are or may be reclassified subsequently to profit or loss.




Exchange Loss Arising on Translation on Foreign Operations

292,049


(421,716)


292,049

 

(421,716)





Other Comprehensive Income for the Period, Net of Tax

292,049


(421,716)





Total Comprehensive Income

(16,465,733)

 

(6,512,890)

 

 

 

 

 

 








Loss for the period attributable to:




Owners of the Parent

(16,317,712)


(6,040,462)

Non-Controlling Interests

(440,070)


(50,712)


(16,757,782)

 

(6,091,174)









Total comprehensive income for the period attributable to:




Owners of the Parent

(16,025,663)


(6,462,178)

Non-Controlling Interests

(440,070)


(50,712)


(16,465,733)

 

(6,512,890)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated Statement of Financial Position



30 June 2025

 

31 December 2023

 





Assets

 




Non-Current Assets

 




Property, Plant and Equipment


10,480,123


199,306

Intangible Assets


1,664,761


23,594,130

Other Non-Current Investments


-


80

Trade and Other Receivables


341,590


101,943



12,486,474

 

23,895,459











Current Assets

 




Trade and Other Receivables


2,599,813


3,293,618

Inventories


2,545,296


1,727,768

Cash and Cash Equivalents


3,071,223


2,799,380



8,216,332

 

7,820,766






Total Assets

 

20,702,806

 

31,716,225

 










Liabilities

 




Non-Current Liabilities

 




Trade and Other Liabilities


292,282


1,996,367

Loans and Borrowings


7,177,596


1,264,449

Deferred Tax Liability


1,405,710


1,799,191

Provisions


561,032


-



9,436,620

 

5,060,007






Current Liabilities

 




Trade and Other Liabilities


2,797,321


6,099,082

Loans and Borrowings


7,045,187


5,368,149

Provisions


-


286,282



9,842,508

 

11,753,513






Total Liabilities

 

19,279,128

 

16,813,520

 





Net Assets

 

1,423,678

 

14,902,705

 

 

 

 

 

 

 

 

 

 





Issued capital and reserves attributable to owners of the parent

 




Share Capital


4,250,018


3,250,018

Share Premium


27,195,826


22,795,826

Shares to be Issued


378,969


831,450

Reverse Takeover Reserve


(4,797,432)


(4,797,432)

Shared Based Payments Reserve


4,149,994


6,110,807

Foreign Exchange Reserve


(129,667)


(421,716)

Retained Earnings


(29,133,248)


(12,815,536)



1,914,460

 

14,953,417






Non-Controlling Interests


(490,782)


(50,712)






Total Equity

 

1,423,678

 

14,902,705

 

 

 

 

 


 

Consolidated Statement of Changes in Equity

 

 

 

 

 

 

 


Share Capital

Share Premium

Shares to be Issued

Reverse Takeover Reserve

Shared Based Payments Reserve

Foreign Exchange Reserve

Retained Earnings

Non-Controlling Interests

Total Equity

At 1 January 2024

3,250,018

22,795,826

831,450

(4,797,432)

6,110,807

(421,716)

(12,815,536)

(50,712)

14,902,705











Comprehensive Income for the Year

 









Profit for the Year

-

-

-

-

-

-

(16,317,712)

(440,070)

(16,757,782)

Exchange Loss Arising on Translation on Foreign Operations

-

-

-

-

-

292,049

-

-

292,049

Total Comprehensive Income for the Year

-

-

-

-

-

292,049

(16,317,712)

(440,070)

(16,465,733)

Issue of Share Capital

1,000,000

4,400,000

-

-

-

-

-


5,400,000

Shares to be Issued as part of the Consideration in a Business Combination

-

-

(452,481)

-

-

-

-

-

(452,481)

Post Combination Remuneration - Equity Component

-

-

-


(1,960,813)

-

-

-

(1,960,813)

Total contributions by and distributions to owners

1,000,000

4,400,000

(452,481)

-

(1,960,813)

-

-

-

2,986,706

 










At 30 June 2025

4,250,018

27,195,826

378,969

(4,797,432)

4,149,994

(129,667)

(29,133,248)

(490,782)

1,423,678


NOTES TO THE FINANCIAL STATEMENTS

For the Eighteen Months ended 30 June 2025.

1.    General Information

Silverwood Brands plc is a listed public limited company (Aquis: SLWD) incorporated in the UK and registered in England and Wales (Company Number 13557318). The Company's registered office is Unit 7 Westergate Business Centre, Westergate Road, Brighton, United Kingdom, BN2 4QN.

The shares of the Company are traded on the Growth Market of the Acquis Stock Exchange with the ticker code SLWD. PL. The consolidated financial statements comprise the Company and its subsidiaries (together referred to as the "Group") and are for the eighteen months ended 30 June 2025.

The principal activity of the Group is the sale and distribution of beauty products.

These financial statements have been prepared for an extended reporting period of 18 months ending 30 June 2025. The prior year comparative figures relate to a 12month period ending 31 December 2023.

The UK entities have aligned their yearend to 30 June 2025 in order to bring the group reporting timetable into line with the financial yearends of the Japanese subsidiaries.

Because the current period is longer than the comparative period, the results presented are not directly comparable, and users of the financial statements should exercise caution when interpreting periodonperiod movements.

2.    Basis of preparation

These financial statements have been prepared in accordance with UK adopted international accounting standards.

The financial statements are presented in Pounds Sterling and all values are rounded to the nearest pound.

3.    Basis of consolidation

3.1 - Business Combinations

The Group applies the acquisition method to account for business combinations. A business combination is recognised when the Group obtains control of an acquired company or trade and the acquired set of activities and assets is capable of being managed as a business. In assessing whether an acquisition meets the definition of a business, the Directors consider whether the acquired set includes inputs and processes that together have the ability to create outputs.

The consideration transferred is measured at fair value at the acquisition date. Identifiable assets and liabilities are recognised at their fair values at that date. Any excess of the consideration transferred over the fair value of the identifiable net assets acquired is recognised as goodwill. Goodwill is not amortised and is tested annually for impairment.

Where the fair value of the identifiable net assets acquired exceeds the consideration transferred, the difference is recognised immediately in profit or loss as a gain on bargain purchase.

Acquisitionrelated costs are expensed as incurred and presented within Exceptional Costs in the profit or loss.

Contingent consideration is recognised at fair value at the acquisition date. Where the Group expects to settle contingent consideration in equity instruments, the amount is recognised within equity and is not subsequently remeasured. Where settlement is expected in cash, the liability is remeasured at fair value at each reporting date, with changes recognised in profit or loss

 

3.2 - Subsidiaries

Subsidiaries are entities over which the Group has control. Control comprises an investor having power over the investee and is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power. Subsidiaries are fully consolidated from the date on which control is transferred to the Group.

 

3.3 Non-Controlling Interests

NCI are measured initially at their proportionate share of the acquiree's identifiable net assets at the date of acquisition.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3.4 - Entities within the Group

The Group financial statements consolidate those of the Company and its subsidiaries undertakings drawn up to 30 June 2025. The group subsidiaries and the Company's shareholding is shown in the table below.

Undertaking

Country of Incorporation

Holding

Proportion of voting rights and shares held 2025

Proportion of voting rights and shares held 2023

Balmonds Skincare Ltd

United Kingdom

Ordinary Shares

100%

100%

NBY London Ltd

United Kingdom

Ordinary Shares

100%

100%

Cosmic Circles Ltd

United Kingdom

Ordinary Shares

100%

100%

Sonotas Holdings

Japan

Ordinary Shares

90%

90%

Community Beauty Limited

United Kingdom

Ordinary Shares

100%

-

 

The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, are translated into GBP at the exchange rates at the reporting date. The income and expenses of foreign operations are translated into GBP at the exchange rates at the dates of the transactions.

Foreign currency differences are recognised in OCI and accumulated in the translation reserve, except to the extent that the translation difference is allocated to NCI.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings